Primary study · included by 1 review
Can Aspirin Use Be Associated With the Risk or Prognosis of Bladder Cancer? A Case-Control Study and Meta-analytic Assessment.
Fan 2021 · Fan Bo, Mohammed Alradhi, Huang Yuanbin, et al. · Frontiers in oncology · 2021
Included by
| Outcome this study informs | Pooled effect | Evidence | Certainty |
|---|---|---|---|
Risk of bladder cancer With pioglitazone vs Without pioglitazone | OR 1.17 | NR | GRADE not reported |
Risk of bladder cancer With pioglitazone vs Without pioglitazone | OR 1.13 [1.03, 1.25] | 20 studies · 4846088 participants | Low |
Risk of bladder cancer With pioglitazone vs Without pioglitazone | OR 1.84 [0.99, 3.42] | 2 studies · 9114 participants | Moderate |
Risk of bladder cancer Aspirin use, mean duration ≥5 years vs Non-users (reference per source meta-analysis) | RR 0.92 [0.88, 0.96] | 7 studies · 1028458 participants | Very low |
Risk of bladder cancer With pioglitazone vs Without pioglitazone | OR 1.12 | NR | GRADE not reported |
Risk of bladder cancer With pioglitazone vs Without pioglitazone | OR 1.62 | NR | GRADE not reported |
Risk of bladder cancer With pioglitazone vs Without pioglitazone | OR 1.49 | NR | GRADE not reported |
Risk of bladder cancer With pioglitazone vs Without pioglitazone | OR 1.27 | NR | GRADE not reported |
Risk of bladder cancer With pioglitazone vs Without pioglitazone | OR 1.28 | NR | GRADE not reported |
Risk of bladder cancer With pioglitazone vs Without pioglitazone | OR 1.25 | NR | GRADE not reported |
Risk of bladder cancer With pioglitazone vs Without pioglitazone | OR 1.20 | NR | GRADE not reported |
Risk of bladder cancer Aspirin use, mean duration <5 years vs Non-users (reference per source meta-analysis) | RR 0.90 [0.84, 0.96] | 8 studies · 1105506 participants | Very low |
Risk of bladder cancer With pioglitazone vs Without pioglitazone | OR 1.66 | NR | GRADE not reported |
1 including review in total.